ACAllie Y. Chen

Allie Y. Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Allie Y. Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Investigation of Dipicolinic Acid Isosteres for the Inhibition of Metallo‐β‐Lactamases

    by Allie Y. Chen, Pei W. Thomas, Zishuo Cheng, Nasa Y. Xu, David L. Tierney, Michael W. Crowder, Walter Fast, Seth M. Cohen

    New Delhi metallo‐β‐lactamase‐1 (NDM‐1) poses an immediate threat to our most effective and widely prescribed drugs, the β‐lactam‐containing class of antibiotics. There are no clinically relevant inhibitors to combat NDM‐1, despite significant efforts toward their development. Inhibitors that use a carboxylic acid motif for binding the ZnII ions in the active site of NDM‐1 make up a large portion of the >500 inhibitors reported to date. New and structurally diverse scaffolds for inhibitor development are needed urgently. Herein we report the isosteric replacement of one carboxylate group of dipicolinic acid (DPA) to obtain DPA isosteres with good inhibitory activity against NDM‐1 (and related metallo‐β‐lactamases, IMP‐1 and VIM‐2). It was determined that the choice of carboxylate isostere influences both the potency of NDM‐1 inhibition and the mechanism of action. Additionally, we show that an isostere with a metal‐stripping mechanism can be re‐engineered into an inhibitor that favors ternary complex formation. This work provides a roadmap for future isosteric replacement of routinely used metal binding motifs (i.e., carboxylic acids) for the generation of new entities in NDM‐1 inhibitor design and development.


  • Top Cited Papers

    Targeting Metalloenzymes for Therapeutic Intervention

    by Allie Y. Chen, Rebecca N. Adamek, Benjamin L. Dick, Cy V. Credille, Christine N. Morrison, Seth M. Cohen

    Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many others. The role of metalloenzymes in these processes also makes them central for the progression of many diseases and, as such, makes metalloenzymes attractive targets for therapeutic intervention. Increasing awareness of the role metalloenzymes play in disease and their importance as a class of targets has amplified interest in the development of new strategies to develop inhibitors and ultimately useful drugs. In this Review, we provide a broad overview of several drug discovery efforts focused on metalloenzymes and attempt to map out the current landscape of high-value metalloenzyme targets.


  • Correction to Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1

    by Allie Y. Chen, Pei W. Thomas, Alesha C. Stewart, Alexander Bergstrom, Zishuo Cheng, Callie Miller, Christopher R. Bethel, Steven H. Marshall, Cy V. Credille, Christopher L. Riley, et al.


  • Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1

    by Allie Y. Chen, Pei W. Thomas, Alesha C. Stewart, Alexander Bergstrom, Zishuo Cheng, Callie Miller, Christopher R. Bethel, Steven H. Marshall, Cy V. Credille, Christopher L. Riley, et al.

    The efficacy of β-lactam antibiotics is threatened by the emergence and global spread of metallo-β-lactamase (MBL) mediated resistance, specifically New Delhi metallo-β-lactamase-1 (NDM-1). By utilization of fragment-based drug discovery (FBDD), a new class of inhibitors for NDM-1 and two related β-lactamases, IMP-1 and VIM-2, was identified. On the basis of 2,6-dipicolinic acid (DPA), several libraries were synthesized for structure–activity relationship (SAR) analysis. Inhibitor 36 (IC50 = 80 nM) was identified to be highly selective for MBLs when compared to other Zn(II) metalloenzymes. While DPA displayed a propensity to chelate metal ions from NDM-1, 36 formed a stable NDM-1:Zn(II):inhibitor ternary complex, as demonstrated by 1H NMR, electron paramagnetic resonance (EPR) spectroscopy, equilibrium dialysis, intrinsic tryptophan fluorescence emission, and UV–vis spectroscopy. When coadministered with 36 (at concentrations nontoxic to mammalian cells), the minimum inhibitory concentrations (MICs) of imipenem against clinical isolates of Eschericia coli and Klebsiella pneumoniae harboring NDM-1 were reduced to susceptible levels.